The decision means that Hikma may continue marketing colchicine 0.6 mg capsules under the brand name Mitigare™, as well as its authorised generic. According to IMS Health, sales of colchicine in the U.S. market were approximately $651 million for the 12 months ending May 2016. Said Darwazah, Chairman and CEO of Hikma said, "I am very pleased that Hikma can continue marketing its colchicine products in the U.S. market.”